65
Participants
Start Date
August 15, 2019
Primary Completion Date
April 30, 2020
Study Completion Date
April 11, 2023
CS3007 (BLU-285)
"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
Beijing Cancer Hospital, Beijing
Chinese PLA General Hospital, Beijing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Fujian Medical University Union Hospital, Fuzhou
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou
Harbin Medical University Cancer Hospital, Harbin
Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Nanchang Medical University, Nanchang
Liaoning Cancer Hospital & Institute, Shenyang
Fudan University Shanghai Cancer Center, Shanghai
Fudan University Zhongshan Hospital (General Surgery Department), Shanghai
Fudan University Zhongshan Hospital (Internal Tumor Department), Shanghai
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
Xinjiang Medical University Cancer Hospital, Ürümqi
The First Affiliated Hospital Zhe Jiang University, Hangzhou
Lead Sponsor
Collaborators (1)
Blueprint Medicines Corporation
INDUSTRY
CStone Pharmaceuticals
INDUSTRY